Spero Therapeutics (NASDAQ:SPRO) Given New $6.00 Price Target at HC Wainwright

Spero Therapeutics (NASDAQ:SPRO) had its price target raised by research analysts at HC Wainwright from $5.00 to $6.00 in a report released on Monday, Marketbeat reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price objective would suggest a potential upside of 430.97% from the stock’s previous close.

Separately, Weiss Ratings raised shares of Spero Therapeutics from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Wednesday, August 12th. One investment analyst has rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $6.00.

Spero Therapeutics Price Performance

Shares of NASDAQ:SPRO opened at $1.13 on Monday. The business’s fifty day moving average price is $1.36 and its two-hundred day moving average price is $2.12. Spero Therapeutics has a fifty-two week low of $1.08 and a fifty-two week high of $3.08. The stock has a market capitalization of $65.81 million, a price-to-earnings ratio of 10.27 and a beta of 1.49.

Spero Therapeutics (NASDAQ:SPRO) last issued its earnings results on Wednesday, August 12th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.01. Spero Therapeutics had a net margin of 24.90% and a return on equity of 16.17%.

Hedge Funds Weigh In On Spero Therapeutics

A number of institutional investors have recently modified their holdings of SPRO. Invesco Ltd. acquired a new position in shares of Spero Therapeutics during the second quarter worth approximately $43,000. Susquehanna Fundamental Investments LLC acquired a new stake in shares of Spero Therapeutics in the second quarter valued at approximately $36,000. Millennium Management LLC bought a new stake in shares of Spero Therapeutics during the 4th quarter valued at $56,000. Global Retirement Partners LLC acquired a new position in shares of Spero Therapeutics in the 2nd quarter valued at $55,000. Finally, Dimensional Fund Advisors LP bought a new position in shares of Spero Therapeutics in the 3rd quarter worth $55,000. 25.60% of the stock is owned by institutional investors.

Spero Therapeutics Company Profile

Spero Therapeutics is a clinical?stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug?resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.

The company’s lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram?negative pathogens.